CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 4,887 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 4,887 shares of CeriBell stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $26.96, for a total value of $131,753.52. Following the sale, the chief technology officer directly owned 203,118 shares in the company, valued at approximately $5,476,061.28. The trade was a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Raymond Woo also recently made the following trade(s):

• On Thursday, October 1st, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.38, for a total value of $119,145.06.
• On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.33, for a total value of $118,900.71.
• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total value of $47,535.58.

CeriBell Trading Down 3.1%

NASDAQ CBLL opened at $27.39 on Thursday. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a twelve month low of $10.94 and a twelve month high of $28.89. The firm has a market capitalization of $1.05 billion, a PE ratio of -14.12 and a beta of 0.86. The stock’s 50 day moving average is $25.13 and its 200 day moving average is $20.87.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative return on equity of 50.37% and a negative net margin of 67.96%. The firm had revenue of $29.34 million during the quarter, compared to analysts’ expectations of $29.18 million. Research analysts forecast that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sei Investments Co. boosted its position in shares of CeriBell by 2.3% during the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after acquiring an additional 1,125 shares during the last quarter. Strs Ohio bought a new stake in CeriBell in the 1st quarter valued at $27,000. Legal & General Group Plc bought a new stake in CeriBell in the 2nd quarter valued at $53,000. State of Wyoming purchased a new stake in CeriBell in the 1st quarter worth $62,000. Finally, Quantinno Capital Management LP boosted its holdings in shares of CeriBell by 3.0% during the 1st quarter. Quantinno Capital Management LP now owns 140,347 shares of the company’s stock valued at $2,573,000 after purchasing an additional 4,119 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have recently commented on CBLL shares. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. Raymond James Financial reiterated a “strong-buy” rating and issued a $29.00 price target on shares of CeriBell in a research report on Thursday, September 3rd. Canaccord Genuity Group upped their price target on shares of CeriBell from $26.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday. TD Cowen increased their price objective on shares of CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Finally, Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $31.25.

Key Headlines Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $33 from $26 and maintained a Buy rating, signaling confidence in potential upside. Read More.
• Positive Sentiment: Q3 revenue of $29.34 million narrowly topped analyst expectations of $29.18 million, indicating continued sales growth. Read More.
• Neutral Sentiment: CTO Raymond Woo sold 4,887 shares for about $132,000, a 2.35% reduction in his holdings; he retained 203,118 shares afterward. Read More.
• Negative Sentiment: The company reported a quarterly loss of $0.55 per share, wider than the cited consensus estimate of $0.51, while its net loss increased year over year. New-launch expenses contributed to the higher loss, potentially keeping pressure on profitability despite the revenue beat. Read More.

About CeriBell

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.